Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
X Bioscience PCLBKK:XBIO EV-to-FCF is -8.48 as of Aug. 24, 2026. The stock has 6 warning signs investors should review. Among 272 Restaurants companies, X Bioscience PCL ranks worse than 367646.69% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, X Bioscience PCL's Enterprise Value is ฿983.3 Mil.
X Bioscience PCL's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ฿-116.0 Mil. Therefore, X Bioscience PCL's EV-to-FCF for today is -8.48.
The historical rank and industry rank for X Bioscience PCL's EV-to-FCF or its related term are showing as below:
BKK:XBIO'
s EV-to-FCF Range Over the Past 10 Years
Min: -1333.73 Med: -9.55 Max: 35.53
Current: -8.69
During the past 13 years, the highest EV-to-FCF of X Bioscience PCL was 35.53. The lowest was -1333.73. And the median was -9.55.
BKK:XBIO's EV-to-FCF is ranked worse than 100% of 272
companies
in the Restaurants industry
Industry Median: 18.135
vs BKK:XBIO: -8.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
X Bioscience PCL's PE Ratio (TTM) for today is calculated as:
X Bioscience PCL's share price for today is ฿0.07.
X Bioscience PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
X Bioscience PCL EV-to-FCF Related Terms
X Bioscience PCL EV-to-FCF Historical Data
* Premium members only.
The historical data trend for X Bioscience PCL's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Restaurants subindustry, X Bioscience PCL's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X Bioscience PCL EV-to-FCF vs Restaurants Industry
For the Restaurants industry and Consumer Cyclical sector, X Bioscience PCL's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where X Bioscience PCL's EV-to-FCF falls into.
X Bioscience PCL's current Enterprise Value is ฿983.3 Mil.
X Bioscience PCL's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-116.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X Bioscience PCL (BKK:XBIO) has a EV-to-FCF of -8.48 as of Aug. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on X Bioscience PCL and its competitors. According to the industry distribution chart, X Bioscience PCL ranks #999999 out of 272 companies in the Restaurants industry.
Is X Bioscience PCL's EV-to-FCF too high?
X Bioscience PCL's current EV-to-FCF is -8.48. Based on the distribution chart, X Bioscience PCL ranks #999999 out of 272 companies in the Restaurants industry, which is in the bottom quartile relative to peers.
How does X Bioscience PCL's EV-to-FCF compare to SYY and USFD?
According to the Restaurants industry distribution chart, X Bioscience PCL ranks #999999 out of 272 companies for EV-to-FCF. This places X Bioscience PCL in the lower half of its industry. The industry median EV-to-FCF is 18.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Restaurants company?
The median EV-to-FCF among Restaurants companies is 18.14, based on 272 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on X Bioscience PCL and its competitors. For the Restaurants industry, the median EV-to-FCF is 18.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X Bioscience PCL's current EV-to-FCF is -8.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X Bioscience PCL stock overvalued right now?
Based on GuruFocus' analysis, X Bioscience PCL (BKK:XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ฿0.10, compared to a current price of ฿0.07 — trading 30% below its estimated fair value. The current EV-to-FCF is -8.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For X Bioscience PCL (BKK:XBIO), the current EV-to-FCF is -8.48 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X Bioscience PCL, along with its subsidiaries, is mainly engaged in selling food and beverages by operating restaurants and bakery shops under the Le Boeuf, Kagonoya, Bake Cheese Tart, Croquant Chou ZakuZaku, and RAPL trademarks. Additionally, the Group is involved in the production and distribution of biological products. It operates in two business segments: the food and beverage sales segment, which generates maximum revenue, and the production and distribution of biological products segment. Geographically, the Group operates only in Thailand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:XBIO has been successfully added to your 
